ClinicalTrials.Veeva

Menu

Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices (REMIND)

Mass General Brigham logo

Mass General Brigham

Status

Completed

Conditions

Prostatic Hypertrophy, Benign
Breast Cancer
Epilepsy
Diabetes
Mental Health Disorder
Parkinson's Disease
Depression
Cardiovascular Disease

Treatments

Behavioral: Pillbox
Behavioral: RxTimerCap
Behavioral: Take-N-Slide

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02015806
2013-P-00009085

Details and patient eligibility

About

The aim of this study is to determine whether adherence to oral maintenance medications differs for patients randomized to receive a RxTimerCap, a Take-N-Slide, a standard pillbox, or none of these devices, with the hypothesis that low-touch devices improve adherence over control and that the increase in adherence is agnostic across devices.

Full description

Prior to randomization, all patients meeting the inclusion criteria stratified into two strata and two blocks within each strata. The first stratum will consist of all patients on 1 to 3 medications for cardiovascular or other non-depression chronic conditions who are suboptimally adherent to these therapies. The second stratum will include all patients whose only targeted medications are for depression and who are suboptimally adherent to this therapy. Given that the Take-N-Slide device only has a Yes/No toggle for each day of the week and can therefore only be used once per day, each stratum will be further stratified into two separate blocks based on the frequency with which the study participants' medications are (or could possibly be) taken. Patients who are on a medication that is used more than once daily will be randomized in a 2:1 ratio to receive the RxTimerCap, pillbox, or to continue with usual care. Patients for whom all medications are dosed once daily will be randomized in a 2:1 ratio to receive the Take-N-Slide, RxTimerCap, pillbox, or to continue with usual care.

Enrollment

53,480 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have 1 to 3 oral maintenance medications for chronic disease in the 12-month period prior to study eligibility evaluation

    • Cardiovascular disease (defined as hypertension, hyperlipidemia, coronary artery disease, congestive heart failure, or diabetes); OR
    • Another non-depression chronic condition (defined as breast cancer, benign prostatic hypertrophy, schizophrenia, bipolar disorder, anxiety, arrythmia; Parkinson's disease, seizure, and epilepsy); OR
    • Depression
  • Be suboptimally adherent to their qualifying medications, defined as a Medication Possession Ratio between 30% and 80% during the 12 months preceding identification of study eligibility

  • Eligible for pharmacy benefits during the 12 months prior to being identified as being eligible for the study and expected to be eligible for pharmacy benefits through the end of the evaluation period.

Exclusion criteria

  • Enrolled in Ready Fill at Mail (a pharmacy benefit program whereby members elect to have medications shipped automatically to them at the time of refill due date or prescription renewal).

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

53,480 participants in 14 patient groups

All meds but depression, 1x daily use, RxTimerCap
Experimental group
Description:
Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
Treatment:
Behavioral: RxTimerCap
All meds but depression, 1x daily use, Take-N-Slide
Experimental group
Description:
Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
Treatment:
Behavioral: Take-N-Slide
All meds but depression, 1x daily use, pillbox
Experimental group
Description:
Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
Treatment:
Behavioral: Pillbox
All meds but depression, 1x daily use, control
No Intervention group
Description:
Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
All meds but depression, ≥1 med >1 daily use, RxTimerCap
Experimental group
Description:
Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
Treatment:
Behavioral: RxTimerCap
All meds but depression, ≥1 med >1 daily use, pillbox
Experimental group
Description:
Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
Treatment:
Behavioral: Pillbox
All meds but depression, ≥1 med >1 daily use, control
No Intervention group
Description:
Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
Only depression meds, 1x daily use, RxTimerCap
Experimental group
Description:
Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
Treatment:
Behavioral: RxTimerCap
Only depression meds, 1x daily use, Take-N-Slide
Experimental group
Description:
Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
Treatment:
Behavioral: Take-N-Slide
Only depression meds, 1x daily use, pillbox
Experimental group
Description:
Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
Treatment:
Behavioral: Pillbox
Only depression meds, 1x daily use, control
No Intervention group
Description:
Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
Only depression meds, ≥1 med >1 daily use, RxTimerCap
Experimental group
Description:
Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
Treatment:
Behavioral: RxTimerCap
Only depression meds, ≥1 med >1 daily use, pillbox
Experimental group
Description:
Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
Treatment:
Behavioral: Pillbox
Only depression meds, ≥1 med >1 daily use, control
No Intervention group
Description:
Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems